PIN34 Pharmacoeconomic Analysis of The Use of Voriconazole, Posaconazole And Micafungin In The Primary Prophylaxis of Invasive Fungal Infections In Recipients of Allogeneic Hematopoietic Stem Cell Transplants In Spain  by Grau, S et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A581
Objectives: To find out the average direct hospitalization cost and length of hos-
pital stay for patients infected with Carbapenem-resistant Klebsiella pneumonia 
(CRKp) and compare it with that of patients infected with Carbapenem-sensitive 
Klebsiella pneumonia (CSKp). MethOds: A cross sectional study was carried out 
from January-December 2014 and the data for hospitalization cost was collected for 
the patients with CRKp and CSKp infections from the medicine ICU for 72 patients 
admitted to the hospital. The data was analyzed for the site of infection, length of 
stay and average direct hospitalization cost which was then compared between the 
two groups. Results: During the study period, 101 patients were diagnosed with 
Klebsiella pneumoniae infection. 61.79% of the infections were respiratory, 24.52% 
urinary tract- related, 13.2% systemic and 0.47% skin and soft tissue-related. The 
mean age of the study population was 51.7 ± 15.7 years. The median length of stay 
for CRKp was 12 (11; 23) days as compared to 8 (5.2; 13.2) days in CSKp patients . The 
median direct hospitalization cost was calculated to be INR 43,274 (24,898; 16,0315) 
in case of CRKp versus INR 23,452 (12,489; 47,349) in CSKp patients. cOnclusiOns: 
We observed that the average cost of overall therapy and the average no. of hos-
pitalization days was higher in CRKp group compared to CSKp group. Antibiotic 
resistance is a growing phenomenon and the resistance to Carbapenems can lead 
to increased burden of morbidity and treatment cost for patients.
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Objectives: Antibiotic resistance is known to be associated with increased burden 
of morbidity, mortality and treatment costs all over the world. Methicillin resistant 
Staphylococcus aureus is one of the most important gram positive bacteria which 
causes serious community acquired as well as hospital acquired infections. The 
objective of this study is to compare the direct costs and length of stay in MRSA ver-
sus MSSA infections among in-patients of the hospital. MethOds: A cross sectional 
study was carried out from Jan-Dec 2013 and the hospitalization cost was collected 
for the patients with MRSA and MSSA infections from the medicine ICU and the 
microbiology department for 63 patients. The data was analyzed for the type of 
infection and the average hospitalization cost. The median hospitalization cost was 
calculated for both the group of patients. Results: Out of the 63 patients observed, 
44 (69.84%) patients were infected with MRSA and 19 (30.15%) were infected with 
MSSA. The median length of stay was 10 days in MRSA group as compared to 
7.5 days in MSSA group. The median hospitalization cost for MRSA infection was 
INR 16,383 and for MSSA it was INR 11,481. cOnclusiOns: Methicillin resistance in 
Staphylococcus aureus is associated with increased length of stay and hospitaliza-
tion costs. Increased length of stay leads to further increase in the treatment costs 
and morbidity of the patients as it may lead to nosocomial infections.
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Objectives: To compare the cost of the primary prophylaxis of invasive fungal infec-
tions (IFI) with voriconazole, posaconazole, and micafungin in patients undergoing 
allogeneic hematopoietic stem cell transplantation (HSCT) in hospitals of the National 
Health System (NHS) in Spain. MethOds: A cost analysis was made for 100 days and 
180 days of prophylaxis and a decision tree model was developed. The efficacy rate 
of IFI prophylaxis, mortality rate from all causes in patients with/without IFI and 
survival rate with liposomal amphotericin B treatment of prophylaxis failures were 
obtained from randomized trials and a mixed treatment comparisons meta-analysis. 
The model simulation was interrupted with IFI treatment (prophylaxis failures). The 
costs of medication and its intravenous administration in the hospital (in the case of 
micafungin) were considered. Results: In the non-modeled analysis, the savings 
per patient of prophylaxis with voriconazole ranged from € 1,709 to € 9,655 compared 
with posaconazole oral solution, from € 1,811 to € 9,767 compared with posacona-
zole gastro-resistant tablets and from € 3,376 to € 7,713 compared with micafungin. 
In the modeled analysis, the mean cost per patient of the prophylaxis and treatment 
of IFIs was € 6,987 to € 7,619 with voriconazole, € 7,749 with posaconazole, and € 
22,424 with micafungin. Therefore, the savings per patient of prophylaxis with vori-
conazole was € 130 to € 3,664 and € 11,132 to € 30,374 compared with posaconazole 
and micafungin, respectively. The result remained stable after modification of the 
number of days of antifungal prophylaxis and the cost of antifungal treatment of 
failures. cOnclusiOns: According to the model, antifungal prophylaxis with vori-
conazole in recipients of hematopoietic progenitor transplants, compared with posa-
conazole or micafungin, may represent savings for NHS hospitals in Spain.
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Objectives: Darunavir and atazanavir are currently the only protease inhibitors 
(PIs) recommended by the British HIV Association (BHIVA) treatment guidelines. The 
Office of AIDS Research Advisory Council (OARAC) reviewed the US HIV guidelines 
in April 2015 and delisted atazanavir/ritonavir (ATV/r) from the preferred PI options 
as a result of better tolerability (primarily due to discontinuations caused by adverse 
events (AEs)) of darunavir/ritonavir (DRV/r) compared to ATV/r based on findings from 
the ARDENT trial. The objective of this analysis was to quantify the economic impact 
of treating patients with DRV/r compared to ATV/r for two years in the UK based on 
drug costs, AEs and discontinuation due to AEs. MethOds: A simple Markov model 
was built in MS Excel with two health states and 6-month cycles (4 cycles in total): 
on treatment with DRV/r or ATV/r and on subsequent treatment. All patients start on 
DRV/r or ATV/r and some discontinue and move to a subsequent therapy (weighted 
average of 3rd agents in treatment experienced patients, £11.10/day at list price). 
Discontinuation rates from ARDENT were converted to 6-month rates (4.60% for DRV/r 
and 8.78% for ATV/r) using the method from Miller et al. Patients were assumed to 
attend 6 further consultant appointments (£325/visit) in the first three months after 
switching as advised in the BHIVA guidelines for monitoring. AEs from ARDENT were 
also included. Results: Using a list price of £10.57/day for DRV/r and £10.76/day for 
ATV/r), treatment with DRV/r saved £116 per patient in 6 months, £219 in one year 
and £393 over two years. Drivers of savings were the cost of consultant appointments 
and of subsequent treatment. Sensitivity analyses showed how DRV/r was cost saving 
even when the drug cost of DRV/r and ATV/r was assumed equal. cOnclusiOns: In 
conclusion DRV/r has proven to be a highly tolerable and cost saving PI.
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Objectives: Treatment of chronic hepatitis C is changing fast given the amount 
of new drugs coming to the market. Little is known about the budget impact and 
long term implications of the different treatment options. The objective of this 
study was to estimate the budget impact of different treatment options on national 
or regional level and to evaluate the short-term as well as long-term implications 
of different hepatitis C treatments. MethOds: A model flexible for regional and 
national Swedish cohorts of hepatitis C patients was developed. Cost and effect 
inputs were taken from published sources and clinical trial data. Using the model, 
total budget impact as well as cost per cured patient was estimated for different 
treatments. In addition, long term consequences of different treatments were esti-
mated using a Markov model with transition probabilities from the published model 
in the field by Lidgren et al.(1) Results: Given efficacy rates of over 95%, the new 
treatments of hepatitis C will cure more patients in Swedish cohorts compared to 
previous treatments with efficacy rates of around 65%. In the long term, the supe-
rior effectiveness of the new treatments would translate into decreases in cases of 
decompensated cirrhosis, hepatocellular cancer and liver transplants of over 90% 
among these patients. cOnclusiOns: The new treatments of hepatitis C could 
improve virologic outcomes among patients. In the long term, cost-savings from 
reduced burden of disease among these patients are also to be expected. However, 
in the short term these treatments will require twice the budget size compared to 
earlier antiviral therapies in this field. (1.) Lidgren M, Hollander A, Weiland O, Jonsson 
B. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, 
cost-effectiveness and quality of life. Scand J Gastroenterol. 2007 Jul;42(7):876-77
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Objectives: To obtain long-term outcomes of using rilpivirine/tenofovir/emtricit-
abine (single tablet regimen) in treatment of naïve patients with HIV-1 RNA< 100 000 
copies/ml in the Russian Federation. MethOds: Cost analysis was based on the 
results of modeling the treatment of naïve HIV-infected patients with rilpivirine/
tenofovir/emtricitabine (single tablet regimen). Present analysis included assessment 
of direct (ambulatory treatment and hospitalization) and indirect costs (GDP losses). 
Cost data was based on median prices for medicines and medical services in National 
healthcare system in the Russian Federation. Results: The use of rilpivirine/tenofo-
vir/emtricitabine (single tablet regimen) in the analyzed population, due to the better 
adherance and, as a result, better viral suppression, leads to the lower number of new 
HIV-infected persons. Therefore in life-time perspective the potential total costs sav-
ings for the whole population can be up to 8% (€ 1 116 010 172) and 6% (€ 841 581 441) 
compared to efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + 
tenofovir/ emtricitabin (multi-pill regimen), respectively. cOnclusiOns: Obtained 
results showed that better adherence on the treatment scheme rilpivirine/tenofovir/
emtricitabine (single tablet regimen) among naïve patients with HIV-1 RNA< 100 000 
copies/ml can lead to potential significant long-term cost savings.
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